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Antipsychotic medicationCognitive deﬁcits represent a signiﬁcant characteristic of schizophrenia. However, a majority of the clinical
studies have been conducted in antipsychotic drug treated patients. Thus, it remains unclear if signiﬁcant
cognitive impairments exist in the absence of medication. This is the ﬁrst meta-analysis of cognitive ﬁndings in
drug-naïve patients with schizophrenia. Cognitive data from 23 studies encompassing 1106 patients and 1385
controls published from 1992 to 2013 were included. Tests were to a large extent ordered in cognitive domains
according to the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS)
battery. Analysis was performed with STATA using the random-effects model and heterogeneity as well as
Egger's publication bias was assessed. Overall the results show that patients performed worse than healthy
controls in all cognitive domains with medium to large effect sizes. Verbal memory, speed of processing and
working memory were three of the domains with the greatest impairments. The pattern of results is in line
with previous meta-analytic ﬁndings in antipsychotic treated patients. The present meta-analysis conﬁrms the
existence of signiﬁcant cognitive impairments at the early stage of the illness in the absence of antipsychotic
medication.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Kraepelin coined the concept “dementia praecox” in 1896. On the
basis of clinical observations, he had thereby captured the negative
symptoms of schizophrenia and most likely also some of the cognitive
deﬁcits. Half a century later, the evolvement of neuropsychology
allowed for systematic testing of his clinical observations, and cognitive
deﬁcits have since then been convincingly demonstrated in schizophre-
nia and conﬁrmed by meta-analyses (Heinrichs and Zakzanis, 1998;
Mesholam-Gately et al., 2009; Schaefer et al., 2013).
However, since neuroleptic drugs were introduced in the early
1950s a majority of the studies have been conducted in drug treated
patients. In healthy subjects, administration of antipsychoticmedication
has generally been found to have a negative impact on cognitive per-
formance in domains such as speed of processing and attention
(Ramaekers et al., 1999; Saeedi et al., 2006; Vernaleken et al., 2006;
Veselinovic et al., 2013). Importantly, antipsychotic drugs occupy theFatouros-Bergman),
Flyckt), gunnar.edman@ki.se
. This is an open access article underD2-dopamine receptor (Carlsson and Lindqvist, 1963; Farde et al.,
1992). The role of this receptor subtype speciﬁcally in cognitive function
has been conﬁrmed in studies employing Positron Emission Tomogra-
phy (PET), showing that poor cognitive performance in several domains
is associated to lowD2-receptor binding (Volkow et al., 1998; Bäckman,
et al., 2000; Cropley et al., 2006; Takahashi et al., 2007; Cervenka et al.,
2008). In addition, antipsychotic drugs commonly affect also other
neurotransmitter systems of importance for cognitive function, such
as the cholinergic system (Barak, 2009). Thus, it remains unclear if
previous observations of cognitive deﬁcits in schizophrenia solely can
be attributed to the underlying disorder or to some degree represent
an effect of antipsychotic drug treatment.
Until recently, research on cognition in drug-naïve patients with
schizophrenia has been hampered by small samples and by the great
variety of cognitive tests used. Several of the reports have been imaging
studies usually enrolling limited samples (Cleghorn et al., 1989;
Andreasen et al., 1992; Buchsbaum et al., 1992; Parellada et al., 1994;
Barch et al., 2001; Salgado-Pineda et al., 2003; Jones et al., 2004;
Harrison et al., 2006). Although research on drug-naïve high risk to
psychosis subjects has shown cognitive impairments even before
psychosis onset (Bora and Murray, 2014; Bora et al., 2014) meta-
analytic evidence from drug-naïve schizophrenia subjects is lacking.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Sample characteristics.
Characteristic Patients Controls
N Mean (SD) Range N Mean (SD) Range
Sample size 23 48.0 12–214 23 60.2 12–452
Age 21 27.2 (8.7) 16–62 20 27.5 (8.8) 16–62
% male 21 64.3 – 21 60.4 –
Education years 13 12.0 (1.3) 9–14 13 13.7 (2.0) 10–16
DUPa months 8 27.9 (30.6) 4.9–55.2 – – –
a Duration of untreated psychosis.
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drug-naïve patients with schizophrenia have been published (Hill et al.,
2004; Chan et al., 2006; Wang et al., 2007; Hu et al., 2011; Andersen
et al., 2013; Lu et al., 2012; Zhang et al., 2012; He et al., 2013).
The primary aim of the present meta-analysis was to analyze
ﬁndings from studies on cognitive deﬁcits in drug-naïve patients with
schizophrenia.
2. Methods
2.1. Literature search
PubMed and PsycInfo were searched using the following syntax:
(cognition OR cognitive OR neurocognitive OR neuropsychological OR
neuropsychologic OR neurocognition) AND (psychosis OR psychotic
OR schizophrenia) AND (drug naïve OR drug-naïve OR never treated
OR never-treated OR neuroleptic naïve OR neuroleptic-naïve OR anti-
psychotic naïve OR antipsychotic-naïve OR never medicated OR never-
medicated OR treatment naïve OR treatment-naïve). No time limitation
was set. The search was performed on the 1st of November 2012 and
gave 272 hits. The abstracts of the 272 articles were read and the 134
articles judged to be relevant to the topic were read in full length.
To be included in the analysis the studies had to meet the following
criteria: (a) to include patients with schizophrenia spectrum disorders
using DSM-III, DSM-III-R, DSM-IV, ICD-9 or ICD-10 (5 articles were
excluded due to this criterion); (b) to have a sample of drug-naïve
patients. If a study included both drug-naïve and medicated patients,
separate data on the drug-naïve patients had to be available (20 articles
excluded); (c) to include cognitive performance (12 articles excluded);
(d) to include a healthy control group (16 articles excluded); (e) to tap
one of the 7 cognitive domains covered by theMeasurement and Treat-
ment Research to Improve Cognition in Schizophrenia MATRICS battery
(Kern et al., 2008; Nuechterlein et al., 2008). Articles using cognitive
tests not covered by MATRICS were excluded (23 articles excluded);
(f) to have cognitive data presented separately and not only as corre-
lates to other measurements (6 articles excluded); (g) if a sample was
re-used only the article with the largest number of patients was includ-
ed (10 excluded). However, if two studies used overlapping samples but
examined different cognitive domains with different tests, then both
studies were included; (h) only original articles were included, review
articles and case reports were excluded (8 articles excluded); (i) only
articles written in English were included (3 excluded due to this criteri-
on); (j) if data in an articlewere incomplete for the present purpose, the
authors were asked to provide additional information by e-mail (10
articles excluded due to lack of response).
Following this exclusion procedure 21 articles remained for analysis.
Two additional articles were identiﬁed after screening the reference
lists of the 21 articles. The ﬁnal number of articles included in the anal-
ysis was thereby 23.
2.2. Sample
The meta-analysis was based on a total of 1106 patients and 1385
controls. A majority of the patients had the diagnosis of schizophrenia
(89.60%), 2.26% were diagnosed with schizoaffective disorder, 1.35%
with schizophreniform disorder and 5.15% included mixed samples of
schizophrenia, and schizoaffective and schizophreniform disorder. One
study (Brickman et al., 2004) included a majority of patients with
schizophrenia (18 individuals) but also some individuals diagnosed
with bipolar disorder (5 individuals), major depression with psychosis
(1 individual) and psychosis not otherwise speciﬁed (NOS) (1 indi-
vidual). With the exception of 3 studies including a total of 43 patients
where information was lacking, all included studies had enrolled ﬁrst
episode schizophrenia patients, here deﬁned as patients in their
ﬁrst contact with psychiatry. The sample characteristics are presented
in Table 1. Publication year ranged from 1992 to 2013. A detaileddescription of the sample, including country of study origin, details
about duration of untreated psychosis (DUP) and diagnoses, is given
in Tables 1 and 2 in the Supplementary data.
2.3. Neurocognitive tests
Cognitive tests were sorted according to ﬁve of the seven cognitive
domains of the MATRICS battery: verbal memory (VeM) (refers to im-
mediate verbal memory), speed of processing (SoP), working memory
(WM), attention (ATT) and visual memory (ViM) (refers to immediate
visualmemory). Themain purpose of theMATRICS battery is to provide
an outcomemeasure for clinical trials of cognition-enhancing drugs for
schizophrenia and is the result of a unique consensus process. MATRICS
is today the only FDA-approved test battery for measuring cognition in
research on schizophrenia, and sets the standard within the ﬁeld. Our
intention was thus to provide a meta-analysis that could serve as basis
for future cognition studies in schizophrenia using theMATRICS battery.
Thereby, only results from tests used inMATRICS or from tests similar to
the tests included in MATRICS were used.
Two cognitive domains had been poorly assessed by the reviewed
studies. In MATRICS the domain of reasoning and problem solving is
measured by Mazes. This test or any equivalent test had not been
used in any of the studies included in the presentmeta-analysis. Instead,
the cognitive domain of executive functioning (ExF)was included in the
analysis to partly capture the reasoning and problem solving domain.
Moreover, the cognitive domain of social cognition is measured in
MATRICS by Mayer–Salovey–Caruso Emotional Intelligence Test: Man-
aging Emotions. This test had also not been used in the reviewed studies
and no replacement testwas identiﬁed. The included tests and outcome
measures are listed in Table 2.
2.4. Statistical analyses
Meta-analysis was performed with the software STATA, version 12.
The analysis was conducted by the STATA Metan command using the
random-effects model (DerSimonian and Laird, 1986). Cohen's method
was chosen to compute the standardized mean differences (SMD) for
performance in the neurocognitive tests (the difference between pa-
tients and control group means divided by the pooled standard devia-
tion). A value of 0.20–0.50 corresponds to small effect sizes, 0.50–0.80
to medium and a value over 0.80 to large effect sizes. Tests for which
low scores indicate better performance were transformed by adding a
minus, so that high scores always correspond to better performance.
Similar but not identical tests for the same outcome measure were
grouped (e.g. CPT tasks). The same test could be included several
times in the analysis but with different and non-overlapping outcome
measures.
Heterogeneity was assessed by the I2 statistic describing the per-
centage of variation across studies due to heterogeneity rather than
chance (Higgins and Thompson, 2002; Higgins et al., 2003). A value of
0.25% corresponds to low, 0.50% to moderate and 0.75% to high hetero-
geneity. The weight that was addressed to each SMD in the calculation
of overall SMDs was based on sample size. Publication bias was
Table 2
Tests and outcome measures for the domains included in the meta-analysis.
Domain Tests and outcome measures
Verbal memory Buschke Selective Reminding Test (BSRT) (outcome measure: total recall)
Serial Verbal Learning Task (outcome measure: total recall)
Hopkins Verbal Learning Test—Revised (HVLT-R) (outcome measure: total recall)
Immediate Memory from Repeatable Battery for the Assessment of Neuropsychological Status
(outcome measure: total recall)
Logical Memory Test fromWechsler Memory Scale (WMS) (outcome measure: immediate recall)
California Verbal Learning Test (CVLT) (outcome measure: total recall trials 1–5, list A)
Speed of processing Verbal ﬂuency letter “S” (outcome measure: amount of words)
Verbal ﬂuency animal naming (outcome measure: amount of words)
TMT A (outcome measure: time)
WAIS-R Digit Symbol (outcome measure: nr of digits)
Working memory Letter number span (outcome measure: digits and letters recalled)
Digit span from: WMS or WAIS or WISC-III or WAIS-R (all outcome measure: digits recalled)
Spatial SpanWMS—3rd ed. (outcome measure: length)
Spatial Span CANTAB (SSP) (outcome measure: length)
AX CPT (score: d′ long delay)
Paced Auditory Serial Addition Test (outcome measure: nr. correct responses)
CANTAB (SWM, Spatial Working Memory) (outcome measures: strategy, total errors)
Verbal N—back task (2-back) (outcome measure: d′ sensitivity measure) N—back (1-back)
(outcome measure: % correct responses)
Sternberg WM task (outcome measure: accuracy %)
Attention CANTAB (RVP, outcome measure: RVP A, mean latency)
Several CPT tests: CPT-IP, CPT-37 version, CPT, Vigilance test, Continuous Attention Test
(outcome measure: omission errors, commission errors, A′, d′, hit rate)
Visual memory Rey−Osterrieth Complex Figure (RCFT) (outcome measure: immediate recall)
Figure Recall Test from RBANS (outcome measure: immediate recall)
Pattern Recognition Memory test (PRM) immediate recall (outcome measure: % of correction)
Brief Visuospatial Memory Test Revised (BVMT-R) (outcome measure: total recall)
Visual Reproduction I WMS 3rd (outcome measure: total recall)
Executive functioning CANTAB (IED) (outcome measure: total errors adjusted)
CANTAB (SOC) (outcome measure: problems solved in minimummoves, mean moves)
Tower of London (outcome measure: nr of frames completed)
TMT B (outcome measure: time)
Wisconsin Card Sorting Test (WCST) modiﬁed version & WCST 128 & 64 card versions
(outcome measure: categories completed, total no. of errors, perseverative errors)
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(Egger et al., 1997). This test indicates the presence of asymmetry and
bias in the literature, such as exclusion of non-signiﬁcant studies.
Meta-analytic regressionwas performed using the STATAMetareg com-
mand to evaluate the following moderator variables having sufﬁcient
data included in the reports: age, education years, gender (male ratio)
and publication year. Descriptive statistics for the sample characteristics
were calculated with SPSS, version 20.0
-0,5
-1
-1,5
-2
-2,5
VeM SoP WM* ATT ViM ExF
ES
Fig. 1. Effect sizes (SMD) for the cognitive domains included in themeta-analysis of drug-
naïve patients with schizophrenia each included ES corresponding to one data point
(VeM: n = 567, SMD=−1.03 (95% CI =−1.44,−0.63); SoP: n = 361, SMD =−1.03
(95% CI = −1.23, −0.82); WM: n = 375, SMD = −0.97 (95% CI = −1.25, −0.69)
(including the outlier Sternberg WM task (outcome: accuracy %) from van Veelen et al.
(2011)); ATT: n = 364, SMD = −0.80 (95% CI = −0.95, −0.65); ViM: n = 326,
SMD = −0.78 (95% CI = −1.21, −0.34); ExF: n = 529, SMD = −0.74 (95% CI =
−0.85, −0.62). *Outlier Sternberg WM task (outcome: accuracy %) from van
Veelen et al. (2011) excluded in the ﬁgure, SMD =−5.37 (95% CI =−6.51,−4.22).3. Results
Overall the controls outperformed the patients and there were
medium to large effect sizes in all cognitive domains. An overview of
the results for all domains is given in Fig. 1.
The domains of verbal memory, speed of processing and working
memory had the largest effect sizes (Tables 3–5). Each domain is in
the following presented separately in the order given by the effect size
(Tables 3–8).
For the domain verbal memory (overall SMD= -1.03) (Table 3) the
Egger's coefﬁcient bias did not indicate publication bias. Without the
two outliers, Hopkins Verbal Learning Test-R and Serial Verbal Learning
Task, the heterogeneity dropped to I2 = 77.3%, p = 0.001 (SMD =
−0.75, CI = −1.05 to −0.44) but was still high. Moderator analysis
was not possible to perform due to insufﬁcient observations.
For the cognitive domain speed of processing (overall SMD= -1.03)
(Table 4) the Egger's coefﬁcient bias did not indicate the presence of
publication bias. Heterogeneity was moderate. None of the moderating
variables; age, gender, education and publication year was signiﬁcant,
but there was a trend for age (p = 0.064) indicating that lower age
corresponded to smaller ESs.
The cognitive domain of working memory showed an overall effect
size of SMD=−0.97 (Table 5). Again, the heterogeneity in this domain
was high but dropped to moderate levels when excluding the outlier
Sternberg WM task I2 = 59.1%, p = 0.001 (SMD = −0.79, CI =
−0.96 to −0.61). The Egger's coefﬁcient bias was −4.804 (P N |t| =
0.009) and indicates the presence of asymmetry and publication bias
for this domain. Moderating variables, age [t(12) = 3.50, p = 0.010],
gender [t(12) =−7.90, p b 0.001] and publication year [t(12) = 6.53,
p b 0.001], were signiﬁcant for this cognitive domain. ESs increased
with the percentage of males in the patient group and decreased with
the recency of publication year and lower age of the patient group.
Table 3
Tests and effect sizes for the cognitive domain: verbal memory.
Note. nES = number of effect sizes; k = number of studies; RBANS = Repeatable Battery for the Assessment of Neuropsychological Status; WMS = Wechsler Memory Scale; outcome
measure for all Verbal Memory tests = immediate recall.
Overall  (I2 = 88.4%, p = 0.00)
Buschke Selective Reminding Test
Logical Memory Test from WMS
Serial Verbal Learning Task
Immediate Memory from RBANS
California Verbal Learning Test
Hopkins Verbal Learning Test
Test 
29
452
132
132
67
17
56
N contr.
48
100.00
15.93
29.82
14.85
11.24
13.83
% weight
14.33
nES k z p
−1.03 (−1.44, −0.63)
−0.66 (−0.88, −0.44)
−0.92 (−1.86, 0.02)
−0.66 (−1.02, −0.31)
−1.72 (−2.42, −1.02)
−2.03 (−2.49, −1.57)
SMD (95% CI)
−0.57 (−0.98, −0.16)
567
214
158
62
56
N pat.
48 1 1 2.73 0.006
1 1 4.82 <.001
1 1 8.70 <.001
1 1 5.81 <.001
1 1 3.65 <.001
2 2 1.93 0.054
7 7 4.96 <.001
−2 −1.5 −1 −.5 0 .5 1 1.5 2
Table 4
Tests and effect sizes for the cognitive domain: speed of processing.
Note. nES = number of effect sizes; k = number of studies.
Overall  (I2 = 66.5%, p = 0.000)
Verbal fluency, amount words
Test, outcome measure
TMT A, time
WAIS–R Digit Symbol, no.digits
361 311
311
214
N contr.
105
100.00
50.72
34.43
% weight
14.85
nES k z p
−1.03 (−1.23, −0.82)
−0.81 (−1.02, −0.59)
−1.17 (−1.53, −0.81)
SMD (95% CI)
−1.41 (−1.71, −1.12)
361
232
N pat.
125 2 2 9.54 <.001
5 4 6.32 <.001
7 7 7.23 <.001
14 7 9.91 <.001
0−2 −1.5 −1 −.5 .5 1 1.5 2
Table 5
Tests and effect sizes for the cognitive domain: working memory.
Note. nES = number of effect sizes; k = number of studies; WMS = Wechsler Memory Scale; PASAT = Paced Auditory Serial Addition Test.
Overall  (I2 = 83.8%, p = 0.000)
Letter Number Span, digits & letters recalled
Spatial Span, WMS/SSP, outcome: length
Test, outcome measure
N–back task (2–back, 1–back), outcome: d′
Sternberg WM task, accuracy %
CANTAB, SWM, total errors
PASAT, correct responses
N–back, 1–back, % correct responses
AX CPT (score: d′ long delay)
CANTAB, SWM, strategy
Digit Span from WMS/WAIS, digits recalled
411
201
160
12
48
N contr.
61
56
48
70
60
33
100.00
29.75
19.36
3.67
6.37
% weight
6.28
6.56
6.37
11.69
6.66
3.34
nES k z p
−0.97 (−1.25, −0.69)
−0.88 (−1.23, −0.54)
−0.76 (−0.98, −0.53)
−2.27 (−3.32, −1.23)
−0.74 (−1.15, −0.32)
SMD (95% CI)
−1.36 (−1.79, −0.92)
−0.58 (−0.96, −0.20)
−0.76 (−1.18, −0.35)
−0.32 (−0.95, 0.31)
−0.51 (−0.86, −0.17)
−5.37 (−6.51, −4.22)
375
189
160
12
48
N pat.
42
56
48
46
78
23
1
5
3
1
1
1
1
2
1
1
17
1 2.94 0.003
4 5.05 <.001
2 6.53 <.001
1 6.11 <.001
1 3.00 0.003
1 3.61 <.001
1 3.49 <.001
1 0.99 0.322
1 4.27 <.001
1 9.20 <.001
10 7.06 <.001
−7 −6 −5 −4 −3 −2 −1 10 2 3 4 5 6 7
Table 6
Tests and effect sizes for the cognitive domain: attention.
Note. nES = number of effect sizes; k = number of studies.
Overall  (I2 = 44.3%, p = 0.026)
CPT versions comission errors
CANTAB RVP mean latency
CPT versions omission errors
CPT versions hit rate
Test, outcome measure
CPT versions A′
CPT versions d′
CANTAB RVP A
731
500
33
178
496
57
57
105
N contr.
100.00
19.91
6.14
25.27
17.7
8.41
8.14
14.43
% weight nES k z p
−0.80 (−0.95, −0.65)
−0.70 (−0.89, −0.51)
−1.10 (−2.06, −0.14)
−1.09 (−1.31, −0.86)
−0.52 (−0.71, −0.32)
−0.66 (−1.52, 0.19)
−0.93 (−1.75, −0.11)
−0.74 (−1.02, −0.46)
SMD (95% CI)
364
146
29
181
136
37
37
108
N pat.
4 4 9.57 <.001
2 2 5.22 <.001
2 2 2.23 0.026
2 2 1.52 0.13
2 2 2.26 0.24
2 2 5.25 <.001
3 2 7.16 <.001
17 9 11.51 <.001
0−2 −1.5 −1 −.5 .5 1 1.5 2
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Table 7
Tests and effect sizes for the cognitive domain: visual memory.
Note. nES = number of effect sizes; k = number of studies; RBANS = Repeatable Battery for the Assessment of Neuropsychological Status; WMS = Wechsler Memory Scale; BVMT-
R = Brief Visuospatial Memory Test Revised. Most tests have immediate recall as outcomemeasure. The exception is the Pattern Recognition Memory test having % of correction as out-
come.
Overall I2 = 85.3%, p = 0.000)
Pattern Recognition Memory test
Figure Recall Test, RBANS
Visual reproduction, WMS 3rd
Test, outcome measure
BVMT–R
Rey–Osterrieth Complex Figure
324
60
N contr.
48
72
88
56
100.00
17.63
% weight
16.83
17.83
31.32
16.38
nES k z p
−0.78 (−1.21, −0.34)
−0.41 (−0.75, −0.07)
SMD (95% CI)
−0.58 (−0.99, −0.17)
−0.41 (−0.74, −0.09)
−0.74 (−1.19, −0.30)
−1.86 (−2.31, −1.42)
326
78
N pat.
48
80
64
56
1 1 2.79 0.005
1 1 2.35 0.019
1 1 2.52 0.012
1 1 8.21 <.001
2 2 3.27 0.001
6 6 3.50 <.001
0−2 −1.5 −1 −.5 .5 1 1.5 2
Table 8
Tests and effect sizes for the cognitive domain: executive functioning.
Note. nES = number of effect sizes; k = number of studies; WCST = Wisconsin Card Sorting Test.
Overall  (I2 = 29.7%, p = 0.094)
CANTAB SOC problems/min. moves
CANTAB IED total errors adjusted
CANTAB SOC mean moves
WCST version no. errors
Tower of London no. frames 
WCST version categories completed
TMT B time
Test, outcome measure
WCST version perseverative errors
529 437
15
219
88
73
N contr.
106
106
207
141
100.00
1.78
25.13
10.59
8.93
% weight
12.82
3.55
24.42
12.78
nES k z p
−0.74 (−0.85, −0.62)
−1.37 (−2.20, −0.54)
−0.80 (−1.13, −0.48)
−0.89 (−1.20, −0.58)
−0.49 (−0.82, −0.16)
SMD (95% CI)
−0.59 (−0.87, −0.31)
−0.70 (−1.19, −0.21)
−0.77 (−1.07, −0.47)
−0.64 (−0.87, −0.40)
13
285
87
73
N pat.
101
99
257
159
3 3 4.13 <.001
3 3 2.80 0.005
2 2 2.90 0.004
5 5 5.06 <.001
1 1 3.24 0.001
5 5 4.83 <.001
3 3 5.61 <.001
3 3 5.36 <.001
25 11 13.56 <.001
−2 −1.5 −1 −.5 0 .5 1 1.5 2
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SMD = −0.80 (Table 6). Heterogeneity was low (I2 = 44.3%, p =
0.02). The Egger's coefﬁcient bias was not signiﬁcant which indicates
absence of publication bias. None of the moderating variables, age,
gender, education and publication year, was signiﬁcant for this domain.
For the cognitive domain of visual memory, the overall effect size
was SMD =−0.78 (Table 7). When excluding the outlier Brief Visuo-
spatial Memory Test—Revised the heterogeneity fell to low levels I2 =
2.9%, p= 0.390 (SMD=−0.53, CI =−0.71 to−0.35). The Egger's co-
efﬁcient bias did not indicate the presence of publication bias. Due to in-
sufﬁcient number of observations it was not possible to perform a
moderator analysis.
The overall effect size for the cognitive domain executive function-
ing was SMD =−0.74 (Table 8). Heterogeneity was low (I2 = 29.7%,
p = 0.094). The Egger's coefﬁcient bias did not indicate the presence
of publication bias and none of the moderating variables, age, gender,
education and publication year, was signiﬁcant for this cognitive
domain.
4. Discussion
The present meta-analysis on cognitive performance is the ﬁrst con-
ducted on solely antipsychotic drug-naïve patients with schizophrenia.
Overall, patients performed worse than healthy control subjects across
all cognitive domains. The effect sizesweremedium to large, and largest
for verbal memory, speed of processing and workingmemory. Both the
magnitude of differences and the pattern with pronounced deﬁcits in
verbal memory and speed of processing relative to other cognitive
domains are in line with previous meta-analyses on studies where
most patients were medicated and had been ill for several years(Saykin et al., 1991; Heinrichs and Zakzanis, 1998; Aleman et al.,
1999; Dickinson et al., 2007; Schaefer et al., 2013). The present analysis
conﬁrms that cognitive deﬁcits are present also in drug-naïve patients
with schizophrenia at an early stage of the illness.
When comparing the present meta-analytic ﬁndings to previous
meta-analytic ﬁndings from mostly antipsychotic medicated ﬁrst epi-
sode schizophrenia patients (Mesholam-Gately et al., 2009), the effect
sizes regarding the cognitive domains of verbal memory, visual memo-
ry, executive functioning (only comparing WCST) and attention (only
comparing CPT) are at similar levels. The cognitive domains of working
memory and speed of processing in the present meta-analysis did not
include equivalent tests to Mesholam-Gately et al. (2009), however
effect sizes from individual tests within these domains are still com-
parable. With regard to the subjects' age, education and gender pro-
portions these two meta-analyses are similar (see Table 4 in the
Supplementary data). Approximately 37% of the patients in the
Mesholam-Gately et al. (2009) study were either in a medication free
or drug naïve state, and twelve of the studies (corresponding to approx-
imately 18% of the patients) included only drug-naïve patients, some of
which may have been included also in the present meta-analysis. Al-
though the samples are thus partly overlapping, the strength of the
present analysis is that it conﬁrms that some cognitive impairments
are a characteristic of patients with schizophrenia, in the absence of
medication.
There are to date only few and small studies examining antipsy-
chotic treatment effects in drug-naïve patients with schizophrenia, all
of them suggesting that there are no evident effects of antipsychotic
treatment on cognition in these patients (Hong et al., 2002; Fagerlund
et al., 2004; Hill et al., 2008; Andersen et al., 2011). However, studies
directly examining the effects of antipsychotic drugs on cognition in
161H. Fatouros-Bergman et al. / Schizophrenia Research 158 (2014) 156–162patients usually include medicated patients who are treated with the
test drug after a short washout period. Thus, they do not employ a base-
line evaluation of cognitive performance at drug free conditions (Keefe
et al., 2007a,b). Although meta-analytic comparisons comparing
antipsychotic medicated to unmedicated cohorts do not directly mea-
sure drug treatment effects, they may constitute an additional valuable
source for information.
The broad proﬁle of cognitive deﬁcits may also be present in an
attenuated form in unaffected ﬁrst-degree relatives of patients with
schizophrenia. Indeed, deﬁcits in executive functioning have been
found in healthy ﬁrst-degree relatives in two meta-analyses (Szöke
et al., 2005; Snitz et al., 2006). A third meta-analysis also showed, in
addition to executive functioning, impairments in verbal memory and
to some degree impairments in attention in the healthy ﬁrst degree
relatives (Sitskoorn et al., 2004). These domains can therefore be con-
sidered as candidates for a cognitive endophenotype of schizophrenia.
A limitation of thepresentmeta-analysis is that several of the studies
had not matched their samples regarding age, gender and education
level. This may have inﬂuence on the results since both age and educa-
tion level have been related to cognitive performance. There was thus
some variability among the included samples regarding demographic
characteristics as well as regarding the patients' DUP, all of which may
raise questions about the heterogeneity and the representativeness of
the included samples. Some domains, for example verbal memory,
displayed high within domain heterogeneity indicating a large degree
of variability among the cognitive tests used. Though, an important no-
tion is that heterogeneity may also reﬂect actual task heterogeneity
rather than between subject or between sample differences. Overall
moderator analysis revealed spare results and no recurring patterns,
which partly may be due to insufﬁcient amount of observations. Publi-
cation bias was only displayed in the working memory domain, which
may indicate the presence of asymmetry and bias in the literature,
such as exclusion of non-signiﬁcant studies. Another bias is the use of
benzodiazepines that mostly were not documented in the reviewed ar-
ticles, but still may have had an impact on cognition. For future research
in ﬁrst episode schizophrenia, it is recommended that concomitant
medication is documented in more detail. Another limitation was that
although different but not overlapping outcome measures from the
same test were included in the analysis, these may have been correlat-
ed, since good performance is reﬂected in all the corresponding out-
come measures of a test. Finally, patients are sometimes in stressful
conditions during onset of psychosis and ﬁrst admission. Such con-
ditions may have effect on sleep, on capacity to concentrate, and also
on motivation during testing.
To conclude, the results in the presentmeta-analysis show that anti-
psychotic drug-naïve patients with schizophrenia performmore poorly
than healthy controls in all cognitive domains with medium to large ef-
fect sizes. Verbal memory, speed of processing and working memory
were three of the domains with the greatest impairments. The results
indicate the existence of signiﬁcant cognitive impairments at the early
stages of the illness in the absence of antipsychotic medication.Role of funding source
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